Hematopoietic Stem Cell Transplantation (HSCT) Market Growth Statistics,Size, SWOT Analysis, Forthcoming Developments, Upcoming Investments and Forecast 2027

Multipotent hematopoietic stem cells derived from peripheral blood cells, bone marrow, or umbilical cord blood are implanted into the patient during hematopoietic stem cell transplantation.

                   Hematopoietic Stem Cell Transplantation (HSCT) Market




Multipotent hematopoietic stem cells derived from peripheral blood cells, bone marrow, or umbilical cord blood are implanted into the patient during hematopoietic stem cell transplantation. Lymphoma (Hodgkin and Non-Hodgkin), leukaemia, multiple myeloma, thalassemia, sickle cell anaemia, and osteoporosis are all treated by hematopoietic stem cell transplantation. There are two types of stem cell transplants: 1) autologous, which utilises stem cells from the patient's own body, and 2) allogeneic, which uses stem cells from a donor's body. Every year, approximately 50,000 hematopoietic stem cell transplantation procedures are performed worldwide, according to the World Health Organization (WHO), and this figure is likely to rise in the coming years.


The adverse effects of hematopoietic stem cell transplantation on organs and body parts such as the gastrointestinal tract, mouth, heart, and lungs, which are linked to the conditioning regimen and others, as well as the serious complication of graft vs. host disease, are expected to stifle the Hematopoietic stem cell transplantation (HSCT) market's growth.


Graft-versus-host disease (GVHD) is a consequence of allogeneic and reduced-intensity allogeneic stem cell transplants in which the graft perceives the patient's healthy cells (the host) as alien, attacking and damaging them. A tight HLA match between the donor and the patient reduces but does not eliminate the risk of GVHD. Graft-versus-host disease is a kind of infection that can be mild, moderate, or severe. It can be life-threatening in some circumstances.


Market segmentation:

On the basis of disease indication
  • Leukemia
  • Lymphoproliferative disorders
  • Non-malignant disorders

On the basis of transplant
  • Autologous
  • Allogeneic

On the basis of application
  • Cord blood transplants
  • Peripheral blood stem cells transplants
  • Bone marrow transplants.


The major key players operating in the Hematopoietic Stem Cell Transplantation (HSCT) Market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc., and Stempeutics Research Pvt Ltd.

Comments

Popular posts from this blog

Molecular Sieves Catalyst Market: Global Company Analysis and Forecast 2018 – 2026 | Albemarle Corporation, W. R. Grace and Company, Silkem Ltd., Sinopec Group, and JGC Catalysts & Chemicals Ltd.

Biolubricants Market Size, Share, Growth, Opportunities, Global Analysis and Opportunity Assessment 2019 – 2027

Shared Services Market by Function, By Number of Services and By Region – Global Opportunities & Forecast 2019 - 2027